From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision

Area of Science:

• Molecular Biology
• Genetics
• Endocrinology

Background:

• Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia.
• Noncoding RNAs (ncRNAs), including miRNAs, lncRNAs, circRNAs, and piRNAs, are increasingly recognized as critical regulators in DM pathogenesis.
• These ncRNAs influence pancreatic β-cell function, insulin signaling, and immune responses.

Purpose of the Study:

• To provide a comprehensive review of ncRNA biogenesis, regulatory networks, and functional roles across various DM subtypes.
• To integrate computational and experimental data to map disease-specific ncRNA signatures and their regulatory mechanisms.
• To highlight the potential of ncRNAs as biomarkers and therapeutic targets for diabetes.

Main Methods:

• Systematic in silico integration of curated databases (HMDD v4.0, LncRNADisease) with experimental evidence.
• Analysis of ncRNA signatures and regulatory axes in β-cell dysfunction, insulin resistance, and diabetic complications.
• Review of mechanistic studies and translational insights into ncRNA-mediated pathways.

Main Results:

• ncRNAs play central roles in regulating pancreatic β-cell integrity, insulin signaling, and metabolic homeostasis across diverse DM types.
• Disease-specific ncRNA signatures and their regulatory axes in β-cell dysfunction, insulin resistance, and complications were mapped.
• Circulating and tissue-specific ncRNAs show promise as minimally invasive biomarkers for early detection, stratification, and prognosis.

Conclusions:

• ncRNAs are crucial regulators in diabetes mellitus, impacting multiple facets of the disease.
• ncRNA-based diagnostics and therapeutics offer a promising avenue for precision medicine in diabetes management.
• Further research is needed to address methodological and validation gaps for clinical translation of ncRNA discoveries.